Laboratory Corporation of America (LH) Stock Forecast, Price Target & Predictions
LH Stock Forecast
Laboratory Corporation of America stock forecast is as follows: an average price target of $287.00 (represents a 28.18% upside from LH’s last price of $223.91) and a rating consensus of 'Buy', based on 7 wall street analysts offering a 1-year stock forecast.
LH Price Target
The average price target for Laboratory Corporation of America (LH) is $287.00 based on 1-year price targets from 7 Wall Street analysts in the past 3 months, with a price target range of $350.00 to $249.00. This represents a potential 28.18% upside from LH's last price of $223.91.
LH Analyst Ratings
According to 7 Wall Street analysts, Laboratory Corporation of America's rating consensus is 'Buy'. The analyst rating breakdown for LH stock is 0 'Strong Buy' (0.00%), 4 'Buy' (57.14%), 3 'Hold' (42.86%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Laboratory Corporation of America Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Aug 05, 2024 | Michael Ryskin | Bank of America Securities | $260.00 | $236.00 | 10.17% | 16.12% |
| Aug 02, 2024 | Stephanie Davis | Barclays | $249.00 | $235.67 | 5.66% | 11.21% |
| Aug 02, 2024 | Eric Coldwell | Robert W. Baird | $277.00 | $235.67 | 17.54% | 23.71% |
| Mar 25, 2024 | David Toung | Argus Research | $250.00 | $212.50 | 17.65% | 11.65% |
| Jan 06, 2023 | - | Morgan Stanley | $303.00 | $241.42 | 25.51% | 35.32% |
| Nov 23, 2022 | - | Credit Suisse | $305.00 | $238.00 | 28.15% | 36.22% |
| Jul 29, 2022 | - | Mizuho Securities | $296.00 | $254.72 | 16.21% | 32.20% |
| May 03, 2022 | - | Deutsche Bank | $265.00 | $245.45 | 7.96% | 18.35% |
| May 02, 2022 | - | Credit Suisse | $312.00 | $240.28 | 29.85% | 39.34% |
| Apr 25, 2022 | - | Wells Fargo | $315.00 | $266.12 | 18.37% | 40.68% |
The latest Laboratory Corporation of America stock forecast, released on Aug 05, 2024 by Michael Ryskin from Bank of America Securities, set a price target of $260.00, which represents a 10.17% increase from the stock price at the time of the forecast ($236.00), and a 16.12% increase from LH last price ($223.91).
Laboratory Corporation of America Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 3 | 4 |
| Avg Price Target | - | $262.00 | $259.00 |
| Last Closing Price | $223.91 | $223.91 | $223.91 |
| Upside/Downside | -100.00% | 17.01% | 15.67% |
In the current month, the average price target of Laboratory Corporation of America stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Laboratory Corporation of America's last price of $223.91. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 05, 2024 | Bank of America Securities | Buy | Buy | Hold |
| Aug 02, 2024 | Barclays | Equal-Weight | Equal-Weight | Hold |
| Aug 02, 2024 | UBS | Buy | Buy | Hold |
| Jan 06, 2023 | Morgan Stanley | Overweight | Overweight | Hold |
| Dec 12, 2022 | Citigroup | - | Neutral | Downgrade |
| Nov 23, 2022 | Credit Suisse | Outperform | Outperform | Hold |
| Aug 01, 2022 | Credit Suisse | Outperform | Outperform | Hold |
| May 02, 2022 | Credit Suisse | Outperform | Outperform | Hold |
| Jan 28, 2022 | Deutsche Bank | - | Hold | Downgrade |
Laboratory Corporation of America's last stock rating was published by Bank of America Securities on Aug 05, 2024. The company gave LH a "Buy" rating, the same as its previous rate.
Laboratory Corporation of America Financial Forecast
Laboratory Corporation of America Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | $3.03B | $3.06B | $3.03B | $3.78B | $3.67B | $3.61B | - | $3.90B | $4.06B | $4.06B | $3.84B | $4.16B | $4.49B | $3.90B | $2.77B | $2.82B | $2.95B | $2.93B |
| Avg Forecast | $3.62B | $3.61B | $3.61B | $3.57B | $3.46B | $3.45B | $3.45B | $3.40B | $3.31B | $3.26B | $3.19B | $3.12B | $3.02B | $2.99B | $3.77B | $3.69B | $3.74B | $3.79B | $3.75B | $4.01B | $3.92B | $3.65B | $3.61B | $3.91B | $4.04B | $3.65B | $2.48B | $2.80B | $2.93B | $2.91B |
| High Forecast | $3.67B | $3.66B | $3.66B | $3.62B | $3.51B | $3.50B | $3.50B | $3.45B | $3.35B | $3.29B | $3.23B | $3.16B | $3.03B | $3.02B | $3.82B | $3.74B | $3.79B | $3.84B | $3.75B | $4.08B | $3.99B | $3.71B | $3.68B | $3.98B | $4.11B | $3.72B | $2.53B | $2.85B | $2.98B | $2.96B |
| Low Forecast | $3.58B | $3.58B | $3.57B | $3.54B | $3.43B | $3.42B | $3.41B | $3.37B | $3.27B | $3.22B | $3.15B | $3.09B | $3.01B | $2.93B | $3.73B | $3.65B | $3.70B | $3.75B | $3.75B | $3.92B | $3.83B | $3.57B | $3.53B | $3.83B | $3.95B | $3.57B | $2.43B | $2.74B | $2.86B | $2.85B |
| # Analysts | 5 | 4 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 8 | 5 | 4 | 7 | 11 | 5 | 9 | 5 | 4 | 4 | 8 | 6 | 5 | 5 | 4 | 4 | 7 | 4 | 4 | 3 | 5 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.01% | 1.02% | 0.81% | 1.02% | 0.98% | 0.95% | - | 0.97% | 1.04% | 1.11% | 1.06% | 1.06% | 1.11% | 1.07% | 1.12% | 1.01% | 1.01% | 1.01% |
Laboratory Corporation of America's average Quarter revenue forecast for Mar 24 based on 4 analysts is $3.12B, with a low forecast of $3.09B, and a high forecast of $3.16B. LH's average Quarter revenue forecast represents a 2.80% increase compared to the company's last Quarter revenue of $3.03B (Dec 23).
Laboratory Corporation of America EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 5 | 4 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 8 | 5 | 4 | 7 | 11 | 5 | 9 | 5 | 4 | 4 | 8 | 6 | 5 | 5 | 4 | 4 | 7 | 4 | 4 | 3 | 5 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | $375.70M | $436.70M | $411.70M | $503.00M | $530.30M | $636.00M | - | $856.50M | $916.50M | $996.00M | $915.40M | $1.25B | $1.47B | $1.15B | $493.60M | $-68.40M | $512.90M | $491.90M |
| Avg Forecast | $726.48M | $725.26M | $724.51M | $717.43M | $695.07M | $692.82M | $692.64M | $682.90M | $663.98M | $655.16M | $639.50M | $998.21M | $605.89M | $600.67M | $756.33M | $907.46M | $751.10M | $672.50M | $753.28M | $824.97M | $781.36M | $611.37M | $835.87M | $1.02B | $1.03B | $526.72M | $309.49M | $-53.67M | $501.91M | $483.27M |
| High Forecast | $736.64M | $735.40M | $734.65M | $727.46M | $704.80M | $702.51M | $702.33M | $692.45M | $673.26M | $661.19M | $648.45M | $1.20B | $607.90M | $606.27M | $766.91M | $1.09B | $761.61M | $807.00M | $753.28M | $989.96M | $937.63M | $733.64M | $1.00B | $1.23B | $1.23B | $632.06M | $371.38M | $-42.93M | $602.29M | $579.92M |
| Low Forecast | $719.02M | $717.81M | $717.08M | $710.07M | $687.94M | $685.70M | $685.53M | $675.89M | $657.16M | $647.12M | $632.94M | $798.57M | $603.88M | $587.80M | $748.57M | $725.97M | $743.40M | $538.00M | $753.28M | $659.97M | $625.08M | $489.09M | $668.70M | $819.38M | $823.30M | $421.37M | $247.59M | $-64.40M | $401.53M | $386.62M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.62% | 0.73% | 0.54% | 0.55% | 0.71% | 0.95% | - | 1.04% | 1.17% | 1.63% | 1.10% | 1.22% | 1.43% | 2.18% | 1.59% | 1.27% | 1.02% | 1.02% |
4 analysts predict LH's average Quarter EBITDA for Mar 24 to be $998.21M, with a high of $1.20B and a low of $798.57M. This is 165.69% upper than Laboratory Corporation of America's previous annual EBITDA (Dec 23) of $375.70M.
Laboratory Corporation of America Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 5 | 4 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 8 | 5 | 4 | 7 | 11 | 5 | 9 | 5 | 4 | 4 | 8 | 6 | 5 | 5 | 4 | 4 | 7 | 4 | 4 | 3 | 5 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | $-167.10M | $183.30M | $188.90M | $212.90M | $76.10M | $352.80M | - | $491.60M | $553.60M | $587.30M | $467.40M | $769.60M | $938.30M | $703.40M | $231.60M | $-317.20M | $227.10M | $220.70M |
| Avg Forecast | $370.73M | $376.07M | $401.47M | $369.38M | $333.07M | $334.96M | $346.67M | $326.95M | $291.17M | $297.67M | $318.31M | $581.90M | $274.57M | $280.99M | $323.34M | $529.00M | $297.19M | $396.55M | $341.88M | $480.91M | $471.46M | $360.50M | $426.79M | $628.73M | $654.84M | $322.03M | $145.21M | $-248.88M | $222.23M | $216.83M |
| High Forecast | $377.47M | $382.91M | $408.77M | $376.10M | $339.12M | $341.05M | $352.98M | $332.89M | $296.46M | $315.32M | $324.10M | $698.29M | $283.75M | $290.30M | $329.22M | $634.81M | $302.59M | $475.86M | $341.88M | $577.10M | $565.75M | $432.60M | $512.15M | $754.48M | $785.81M | $386.43M | $174.26M | $-199.10M | $266.68M | $260.19M |
| Low Forecast | $365.78M | $371.05M | $396.11M | $364.45M | $328.62M | $330.49M | $342.05M | $322.58M | $287.28M | $276.64M | $314.07M | $465.52M | $270.40M | $263.22M | $319.03M | $423.20M | $293.22M | $317.24M | $341.88M | $384.73M | $377.16M | $288.40M | $341.43M | $502.98M | $523.87M | $257.62M | $116.17M | $-298.66M | $177.79M | $173.46M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | -0.61% | 0.65% | 0.58% | 0.40% | 0.26% | 0.89% | - | 1.02% | 1.17% | 1.63% | 1.10% | 1.22% | 1.43% | 2.18% | 1.59% | 1.27% | 1.02% | 1.02% |
Laboratory Corporation of America's average Quarter net income forecast for Dec 23 is $274.57M, with a range of $270.40M to $283.75M. LH's average Quarter net income forecast represents a 49.79% increase compared to the company's last Quarter net income of $183.30M (Sep 23).
Laboratory Corporation of America SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 5 | 4 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 8 | 5 | 4 | 7 | 11 | 5 | 9 | 5 | 4 | 4 | 8 | 6 | 5 | 5 | 4 | 4 | 7 | 4 | 4 | 3 | 5 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | $532.90M | $525.50M | $505.80M | $553.60M | $536.50M | $510.00M | - | $464.10M | $543.70M | $519.90M | $458.70M | $429.80M | $518.00M | $419.50M | $396.30M | $395.50M | $413.90M | $401.50M |
| Avg Forecast | $496.34M | $495.51M | $495.00M | $490.16M | $474.89M | $473.35M | $473.23M | $466.57M | $453.64M | $447.62M | $436.92M | $549.35M | $413.96M | $410.39M | $516.74M | $499.41M | $513.17M | $351.04M | $514.65M | $454.01M | $463.53M | $319.13M | $418.85M | $351.13M | $361.51M | $192.05M | $248.48M | $310.32M | $405.03M | $394.46M |
| High Forecast | $503.29M | $502.44M | $501.93M | $497.02M | $481.53M | $479.97M | $479.85M | $473.10M | $459.99M | $451.74M | $443.03M | $659.22M | $415.33M | $414.22M | $523.97M | $599.29M | $520.35M | $421.25M | $514.65M | $544.81M | $556.23M | $382.95M | $502.62M | $421.35M | $433.82M | $230.46M | $298.18M | $372.38M | $486.04M | $473.35M |
| Low Forecast | $491.25M | $490.42M | $489.92M | $485.13M | $470.01M | $468.49M | $468.37M | $461.78M | $448.99M | $442.13M | $432.44M | $439.48M | $412.58M | $401.60M | $511.44M | $399.53M | $507.90M | $280.83M | $514.65M | $363.21M | $370.82M | $255.30M | $335.08M | $280.90M | $289.21M | $153.64M | $198.78M | $248.25M | $324.02M | $315.56M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.29% | 1.28% | 0.98% | 1.11% | 1.05% | 1.45% | - | 1.02% | 1.17% | 1.63% | 1.10% | 1.22% | 1.43% | 2.18% | 1.59% | 1.27% | 1.02% | 1.02% |
Laboratory Corporation of America's average Quarter SG&A projection for Mar 24 is $549.35M, based on 4 Wall Street analysts, with a range of $439.48M to $659.22M. The forecast indicates a 3.09% rise compared to LH last annual SG&A of $532.90M (Dec 23).
Laboratory Corporation of America EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 5 | 4 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 8 | 5 | 4 | 7 | 11 | 5 | 9 | 5 | 4 | 4 | 8 | 6 | 5 | 5 | 4 | 4 | 7 | 4 | 4 | 3 | 5 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | $-1.95 | $2.12 | $2.14 | $2.41 | $0.86 | $3.91 | - | $5.27 | $5.81 | $6.10 | $4.80 | $7.88 | $9.62 | $7.22 | $2.38 | $-3.27 | $2.34 | $2.26 |
| Avg Forecast | $4.40 | $4.46 | $4.76 | $4.38 | $3.95 | $3.97 | $4.11 | $3.88 | $3.45 | $3.53 | $3.78 | $3.48 | $3.26 | $3.33 | $3.84 | $3.40 | $3.53 | $4.01 | $4.04 | $5.13 | $5.13 | $4.22 | $4.79 | $6.40 | $6.97 | $4.56 | $0.86 | $1.85 | $2.40 | $2.44 |
| High Forecast | $4.48 | $4.54 | $4.85 | $4.46 | $4.02 | $4.05 | $4.19 | $3.95 | $3.52 | $3.74 | $3.84 | $3.55 | $3.37 | $3.44 | $3.91 | $3.46 | $3.59 | $4.08 | $4.04 | $5.25 | $5.25 | $4.32 | $4.90 | $6.55 | $7.13 | $4.67 | $0.88 | $1.89 | $2.46 | $2.50 |
| Low Forecast | $4.34 | $4.40 | $4.70 | $4.32 | $3.90 | $3.92 | $4.06 | $3.83 | $3.41 | $3.28 | $3.73 | $3.44 | $3.21 | $3.12 | $3.78 | $3.35 | $3.48 | $3.96 | $4.04 | $4.99 | $4.98 | $4.11 | $4.65 | $6.23 | $6.77 | $4.43 | $0.84 | $1.80 | $2.34 | $2.38 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | -0.60% | 0.64% | 0.56% | 0.71% | 0.24% | 0.98% | - | 1.03% | 1.13% | 1.44% | 1.00% | 1.23% | 1.38% | 1.58% | 2.76% | -1.77% | 0.97% | 0.92% |
According to 7 Wall Street analysts, Laboratory Corporation of America's projected average Quarter EPS for Dec 23 is $3.26, with a low estimate of $3.21 and a high estimate of $3.37. This represents a 53.63% increase compared to LH previous annual EPS of $2.12 (Sep 23).
Laboratory Corporation of America Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| HUM | Humana | $357.86 | $500.84 | 39.95% | Hold |
| LH | Laboratory Corporation of America | $223.91 | $287.00 | 28.18% | Buy |
| DGX | Quest Diagnostics | $152.93 | $154.91 | 1.29% | Buy |
| WAT | Waters | $328.84 | $325.00 | -1.17% | Buy |
| HOLX | Hologic | $81.57 | $78.92 | -3.25% | Buy |
| UHS | Universal Health Services | $229.15 | $208.47 | -9.02% | Hold |
LH Forecast FAQ
Is Laboratory Corporation of America a good buy?
Yes, according to 7 Wall Street analysts, Laboratory Corporation of America (LH) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 4 'Buy' recommendations, accounting for 57.14% of LH's total ratings.
What is LH's price target?
Laboratory Corporation of America (LH) average price target is $287 with a range of $249 to $350, implying a 28.18% from its last price of $223.91. The data is based on 7 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Laboratory Corporation of America stock go up soon?
According to Wall Street analysts' prediction for LH stock, the company can go up by 28.18% (from the last price of $223.91 to the average price target of $287), up by 56.31% based on the highest stock price target, and up by 11.21% based on the lowest stock price target.
Can Laboratory Corporation of America stock reach $300?
LH's highest twelve months analyst stock price target of $350 supports the claim that Laboratory Corporation of America can reach $300 in the near future.
What are Laboratory Corporation of America's analysts' financial forecasts?
Laboratory Corporation of America's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $13.76B (high $13.96B, low $13.62B), average EBITDA is $2.76B (high $2.8B, low $2.74B), average net income is $1.34B (high $1.37B, low $1.32B), average SG&A $1.89B (high $1.91B, low $1.87B), and average EPS is $15.92 (high $16.2, low $15.7). LH's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $14.41B (high $14.62B, low $14.27B), average EBITDA is $2.89B (high $2.93B, low $2.86B), average net income is $1.52B (high $1.55B, low $1.5B), average SG&A $1.98B (high $2B, low $1.96B), and average EPS is $18 (high $18.33, low $17.76).
Did the LH's actual financial results beat the analysts' financial forecasts?
Based on Laboratory Corporation of America's last annual report (Dec 2023), the company's revenue was $12.16B, which missed the average analysts forecast of $13.47B by -9.71%. Apple's EBITDA was $1.7B, missing the average prediction of $2.87B by -40.74%. The company's net income was $418M, missing the average estimation of $1.41B by -70.31%. Apple's SG&A was $2.02B, beating the average forecast of $1.84B by 9.83%. Lastly, the company's EPS was $4.77, missing the average prediction of $13.82 by -65.50%. In terms of the last quarterly report (Dec 2023), Laboratory Corporation of America's revenue was $3.03B, beating the average analysts' forecast of $3.02B by 0.51%. The company's EBITDA was $375.7M, missing the average prediction of $605.89M by -37.99%. Laboratory Corporation of America's net income was $-167M, missing the average estimation of $274.57M by -160.86%. The company's SG&A was $532.9M, beating the average forecast of $413.96M by 28.73%. Lastly, the company's EPS was $-1.95, missing the average prediction of $3.26 by -159.87%